Literature DB >> 33687952

Androgen Receptor Regulates CD44 Expression in Bladder Cancer.

Joseph L Sottnik1, Lauren Vanderlinden2, Molishree Joshi3,4, Ana Chauca-Diaz5, Charles Owens5, Donna E Hansel6, Colin Sempeck7, Debashis Ghosh2, Dan Theodorescu8,9.   

Abstract

The androgen receptor (AR) is important in the development of both experimental and human bladder cancer. However, the role of AR in bladder cancer growth and progression is less clear, with literature indicating that more advanced stage and grade disease are associated with reduced AR expression. To determine the mechanisms underlying these relationships, we profiled AR-expressing human bladder cancer cells by AR chromatin immunoprecipitation sequencing and complementary transcriptomic approaches in response to in vitro stimulation by the synthetic androgen R1881. In vivo functional genomics consisting of pooled shRNA or pooled open reading frame libraries was employed to evaluate 97 genes that recapitulate the direction of expression associated with androgen stimulation. Interestingly, we identified CD44, the receptor for hyaluronic acid, a potent biomarker and driver of progressive disease in multiple tumor types, as significantly associated with androgen stimulation. CRISPR-based mutagenesis of androgen response elements associated with CD44 identified a novel silencer element leading to the direct transcriptional repression of CD44 expression. In human patients with bladder cancer, tumor AR and CD44 mRNA and protein expression were inversely correlated, suggesting a clinically relevant AR-CD44 axis. Collectively, our work describes a novel mechanism partly explaining the inverse relationship between AR and bladder cancer tumor progression and suggests that AR and CD44 expression may be useful for prognostication and therapeutic selection in primary bladder cancer. SIGNIFICANCE: This study describes novel AREs that suppress CD44 and an expected inverse correlation of AR-CD44 expression observed in human bladder tumors. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33687952      PMCID: PMC8782536          DOI: 10.1158/0008-5472.CAN-20-3095

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   13.312


  64 in total

1.  Cross-talk between signal transducer and activator of transcription 3 and androgen receptor signaling in prostate carcinoma cells.

Authors:  T Matsuda; A Junicho; T Yamamoto; H Kishi; K Korkmaz; F Saatcioglu; H Fuse; A Muraguchi
Journal:  Biochem Biophys Res Commun       Date:  2001-04-27       Impact factor: 3.575

Review 2.  Increased androgen receptor transcription: a cause of castration-resistant prostate cancer and a possible therapeutic target.

Authors:  Masaki Shiota; Akira Yokomizo; Seiji Naito
Journal:  J Mol Endocrinol       Date:  2011-07-12       Impact factor: 5.098

3.  Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor.

Authors:  Shibnath Ghatak; Vincent C Hascall; Roger R Markwald; Suniti Misra
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

Review 4.  Role of the androgen receptor in urothelial cancer.

Authors:  Satoshi Inoue; Taichi Mizushima; Hiroshi Miyamoto
Journal:  Mol Cell Endocrinol       Date:  2017-06-23       Impact factor: 4.102

5.  Expression of Androgen Receptor and Cancer Stem Cell Markers (CD44+/CD24- and ALDH1+): Prognostic Implications in Invasive Breast Cancer.

Authors:  Nazia Riaz; Romana Idress; Sadia Habib; Iqbal Azam; El-Nasir Ma Lalani
Journal:  Transl Oncol       Date:  2018-05-31       Impact factor: 4.243

6.  Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer.

Authors:  Daksh Thaper; Sepideh Vahid; Ramandeep Kaur; Sahil Kumar; Shaghayegh Nouruzi; Jennifer L Bishop; Martin Johansson; Amina Zoubeidi
Journal:  Sci Rep       Date:  2018-11-23       Impact factor: 4.379

7.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool.

Authors:  Edward Y Chen; Christopher M Tan; Yan Kou; Qiaonan Duan; Zichen Wang; Gabriela Vaz Meirelles; Neil R Clark; Avi Ma'ayan
Journal:  BMC Bioinformatics       Date:  2013-04-15       Impact factor: 3.169

Review 8.  The biology and role of CD44 in cancer progression: therapeutic implications.

Authors:  Chen Chen; Shujie Zhao; Anand Karnad; James W Freeman
Journal:  J Hematol Oncol       Date:  2018-05-10       Impact factor: 17.388

9.  Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.

Authors:  Joep J de Jong; Joost L Boormans; Bas W G van Rhijn; Roland Seiler; Stephen A Boorjian; Badrinath Konety; Trinity J Bivalacqua; Thomas Wheeler; Robert S Svatek; James Douglas; Jonathan Wright; Marc Dall'Era; Simon J Crabb; Jason A Efstathiou; Michiel S van der Heijden; Kent W Mouw; David T Miyamoto; Yair Lotan; Peter C Black; Ewan A Gibb; Sima P Porten
Journal:  Eur Urol Oncol       Date:  2020-03-20

Review 10.  Cellular rewiring in lethal prostate cancer: the architect of drug resistance.

Authors:  Marc Carceles-Cordon; W Kevin Kelly; Leonard Gomella; Karen E Knudsen; Veronica Rodriguez-Bravo; Josep Domingo-Domenech
Journal:  Nat Rev Urol       Date:  2020-03-16       Impact factor: 14.432

View more
  10 in total

1.  An Integrated Bioinformatics Analysis towards the Identification of Diagnostic, Prognostic, and Predictive Key Biomarkers for Urinary Bladder Cancer.

Authors:  Michail Sarafidis; George I Lambrou; Vassilis Zoumpourlis; Dimitrios Koutsouris
Journal:  Cancers (Basel)       Date:  2022-07-10       Impact factor: 6.575

2.  CD44 potentiates hepatocellular carcinoma migration and extrahepatic metastases via the AKT/ERK signaling CXCR4 axis.

Authors:  Peiyi Xie; Jiuliang Yan; Mengyuan Wu; Hui Li; Zheng Chen; Mincheng Yu; Bo Zhang; Lingli Chen; Lei Jin; Binghai Zhou; Xiaoqiang Li; Yongsheng Xiao; Yongfeng Xu; Jiang Long; Jubo Zhang; Lei Guo
Journal:  Ann Transl Med       Date:  2022-06

3.  CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro?

Authors:  Ruizhi Geng; Niklas Harland; Ivonne A Montes-Mojarro; Falko Fend; Wilhelm K Aicher; Arnulf Stenzl; Bastian Amend
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 4.  Gender Differences in Urothelial Bladder Cancer: Effects of Natural Killer Lymphocyte Immunity.

Authors:  Charles T Lutz; Lydia Livas; Steven R Presnell; Morgan Sexton; Peng Wang
Journal:  J Clin Med       Date:  2021-11-04       Impact factor: 4.964

Review 5.  Strategies for High-Efficiency Mutation Using the CRISPR/Cas System.

Authors:  Shuying Feng; Zilong Wang; Aifang Li; Xin Xie; Junjie Liu; Shuxuan Li; Yalan Li; Baiyan Wang; Lina Hu; Lianhe Yang; Tao Guo
Journal:  Front Cell Dev Biol       Date:  2022-02-07

6.  Establishment of an optimized orthotopic bladder cancer model in mice.

Authors:  Jinming Cai; Zhiwen Xie; Yilin Yan; Zhengnan Huang; Pengfei Tang; Xiangqian Cao; Zeyi Wang; Chenkai Yang; Mingyue Tan; Fang Zhang; Bing Shen
Journal:  BMC Urol       Date:  2022-09-03       Impact factor: 2.090

Review 7.  Sex-biased adaptive immune regulation in cancer development and therapy.

Authors:  Johanna M Schafer; Tong Xiao; Hyunwoo Kwon; Katharine Collier; Yuzhou Chang; Hany Abdel-Hafiz; Chelsea Bolyard; Dongjun Chung; Yuanquan Yang; Debasish Sundi; Qin Ma; Dan Theodorescu; Xue Li; Zihai Li
Journal:  iScience       Date:  2022-07-04

8.  AR regulates CD44.

Authors:  Annette Fenner
Journal:  Nat Rev Urol       Date:  2021-05       Impact factor: 14.432

Review 9.  Sulforaphane Impact on Reactive Oxygen Species (ROS) in Bladder Carcinoma.

Authors:  Hui Xie; Felix K-H Chun; Jochen Rutz; Roman A Blaheta
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 5.923

Review 10.  Nanoparticle-Based RNAi Therapeutics Targeting Cancer Stem Cells: Update and Prospective.

Authors:  Yongquan Tang; Yan Chen; Zhe Zhang; Bo Tang; Zongguang Zhou; Haining Chen
Journal:  Pharmaceutics       Date:  2021-12-08       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.